Immune checkpoint inhibitor (keytruda, opdivo, yervoy, tecentriq, imfinzi, libtayo) denied as non-formulary by UnitedHealthcare?

UnitedHealthcare covers immune checkpoint inhibitors (Keytruda/pembrolizumab, Opdivo/nivolumab, Yervoy/ipilimumab, Tecentriq/atezolizumab, Imfinzi/durvalumab, Libtayo/cemiplimab, and related agents) under the medical benefit when prescribed for cancer indications. This policy provides parameters for coverage of injectable oncology medications, including therapeutic radiopharmaceuticals, covered under the medical benefit based upon the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium, which lists appropriate drugs and biologics for specific cancers using US Food and Drug Administration (FDA)-approved disease indications and specific NCCN panel recommendations. UnitedHealthcare recognizes indications listed in the NCCN Drugs and Biologics Compendium with Categories of Evidence and Consensus of 1, 2A, and 2B as proven and medically necessary, and Category 3 as unproven and not medically necessary. Coverage is provided for the UnitedHealthcare preferred oncology product contingent on the diagnosis-specific criteria; coverage for any non-preferred product is contingent on both the Preferred Product Criteria and Diagnosis-Specific Criteria, and members new to therapy are required to use the preferred product unless they meet exception criteria. Preferred/non-preferred designations vary by indication—for example, in non-small cell lung cancer Keytruda Qlex is preferred; in head and neck cancers Keytruda Qlex is non-preferred; and in squamous cell skin cancer Libtayo is preferred while Keytruda, Keytruda Qlex, Opdivo, Opdivo Qvantig, and Unloxcyt are non-preferred. To qualify for a non-preferred product, the patient must have a history of intolerance or contraindication to a UnitedHealthcare preferred oncology product, and the physician must attest that the same intolerance, contraindication, or adverse event would not be expected with the non-preferred product. Keytruda is administered through the medical benefit but specialty pharmacy distribution is required: UnitedHealthcare classifies Keytruda as a specialty medication requiring prior authorization through OptumRx, typically placed on a high-cost specialty tier (Tier 5). Prior authorization is required, with reauthorization on a periodic basis, and specific PD-L1 expression thresholds (e.g., ≥50% for monotherapy first-line NSCLC) apply per the NCCN/FDA labels referenced in the policy.

- **Cite NCCN Category 1/2A recommendation for the exact indication**: UHC's own policy binds coverage to NCCN Compendium recommendations of Category 1, 2A, or 2B as proven and medically necessary . Quote the specific NCCN guideline page and category (e.g., NCCN NSCLC Guidelines list pembrolizumab + chemo as Category 1 for first-line metastatic non-squamous NSCLC; KEYNOTE-189 trial). - **Reference pivotal trial data supporting the FDA label**: For Keytruda in NSCLC cite KEYNOTE-024 (PD-L1 ≥50% monotherapy) and KEYNOTE-189/407 (combo with chemo); for Opdivo+Yervoy cite CheckMate-227/9LA; for Libtayo cite EMPOWER-Lung-1 and EMPOWER-CSCC-1; for Imfinzi cite PACIFIC (stage III NSCLC after chemoradiation); for Tecentriq cite IMpower150/133. - **Document preferred-product step therapy was met or is contraindicated**: Provide chart notes showing prior trial of the UHC preferred ICI with progression, intolerance, or a contraindication (e.g., active autoimmune disease, hypersensitivity), satisfying UHC's exception pathway as history of intolerance or contraindication to one of the UnitedHealthcare's preferred oncology products, and physician attests that the same intolerance, contraindication, or adverse event would not be expected to occur with the respective non-preferred product. - **Submit biomarker results**: Attach the PD-L1 IHC report (22C3/SP263), MSI/MMR or TMB testing report, and tumor histology confirming the FDA-labeled indication; for monotherapy NSCLC confirm PD-L1 expression positive ≥ 50% . - **Invoke ASCO and NCCN consensus**: ASCO Clinical Practice Guidelines (e.g., ASCO/ESMO guidelines for metastatic NSCLC, melanoma, RCC, HNSCC, urothelial carcinoma) concur with NCCN on ICI use; cite specific guideline year and recommendation grade. - **Cite UHC's medical-benefit step therapy carve-outs**: Continuation-of-therapy provisions apply when the member has been receiving the ICI; reference continuation of prior therapy within the past 365 days as grounds for approval without re-trying the preferred agent. - **Escalate to external/independent review with policy language**: Per practitioner experience, external reviews succeed when patients include a detailed timeline showing how UnitedHealthcare's denial contradicts their own published criteria, and independent medical reviewers appreciate clear, point-by-point rebuttals that reference the plan's policy language directly.

## Why UHC Denied an Immune Checkpoint Inhibitor as Non-Formulary — and How to Appeal

UnitedHealthcare's formulary tiers and exceptions process can result in a non-formulary denial for a checkpoint inhibitor — pembrolizumab (Keytruda), nivolumab (Opdivo), ipilimumab (Yervoy), atezolizumab (Tecentriq), durvalumab (Imfinzi), or cemiplimab (Libtayo) — even when the drug is FDA-approved for your specific indication. Non-formulary status means UHC does not list that specific agent on its preferred drug list for your plan, or it is placed on a tier that requires additional authorization. Critically, non-formulary does not mean uncoverable — virtually every UHC plan has a formulary exception process, and checkpoint inhibitors have strong grounds for exception given their FDA approval and guideline support.

## Why This Denial Is Appealable

Formulary exceptions are a recognized and well-established appeal pathway. UHC must grant a formulary exception when: (a) the formulary alternative is contraindicated or likely to cause adverse effects in your specific case, (b) you have tried the formulary alternative and it was ineffective, or (c) the requested drug is medically necessary and no formulary alternative is therapeutically equivalent for your specific tumor, biomarker, and line-of-therapy combination. Under ACA §2719, non-grandfathered insured plans must allow independent external review of formulary exception denials. Under ERISA §503, self-funded plans must provide full and fair review.

## Federal Appeal Framework

• Formulary exception request: This is typically a parallel or precursor process to a prior authorization appeal. Submit it in writing with supporting documentation at the same time as your PA appeal.
• Internal appeal deadline: Typically 180 days from the denial notice for non-urgent matters. UHC must decide within 30 days for standard pre-service appeals.
• Expedited review: Request expedited review if treatment is urgent — 72-hour decision requirement.
• External review (ACA §2719): If the formulary exception is denied, escalate to independent external review. The external reviewer evaluates whether UHC's formulary determination was clinically appropriate.
• State insurance department: File a complaint if UHC fails to follow its own exception process or applicable state formulary exception laws.

## Documentation to Gather

• UHC formulary and exception criteria: Request your plan's current formulary tier listing and the formulary exception criteria. Your appeal must address each criterion.
• Oncologist letter explaining why the formulary alternative is not appropriate: For checkpoint inhibitors, therapeutic non-equivalence is often straightforward: agents in this class have different targets (PD-1 vs. PD-L1 vs. CTLA-4), different FDA-approved indications, and different biomarker requirements. Your oncologist must document the clinical distinction.
• Biomarker and pathology results: Confirm that the requested agent's companion diagnostic criteria are met and that the formulary alternative does not have an equivalent FDA-approved indication for your specific tumor and biomarker profile.
• NCCN guideline support: Your oncologist should reference the applicable NCCN recommendation for your tumor type, stage, and biomarker, specifying the recommended agent or combination.
• Prior treatment history: If you have tried formulary alternatives and they failed or were inappropriate, document this with dates and outcomes.

## Criteria-Mapping Structure

| Formulary Exception Criterion | Your Documentation | |---|---| | Formulary alternative contraindicated or inappropriate | Oncologist letter: clinical distinction | | Formulary alternative tried and failed | Treatment history with dates/outcomes | | Requested agent has distinct FDA approval for this indication | FDA label indication section | | NCCN recommendation supports requested agent | Guideline category from oncologist | | Biomarker supports requested agent specifically | Lab report |